Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06447415
Other study ID # HRS-7450-102
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date June 15, 2024
Est. completion date March 31, 2025

Study information

Verified date June 2024
Source Fujian Shengdi Pharmaceutical Co., Ltd.
Contact Yu Gao
Phone +0518-81220121
Email yu.gao.yg5@hengrui.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multi-center, randomized, double-blind, double-dummy, placebo-controlled, single dose escalation study aimed at evaluating the overall safety, tolerability, and preliminary efficacy of HRS-7450 in patients with acute ischemic stroke.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 62
Est. completion date March 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Fully understand and voluntarily participate in this study, and sign an informed consent form (the informed consent form can be voluntarily signed by the individual or legal representative); 2. 18 = Age = 80 years old; 3. The onset time is within 4.5 to 24 hours, and medication can be completed within 24 hours of onset (onset time is defined as the patient's last normal time); 4. Clinically diagnosed as acute ischemic stroke (diagnosis follows the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018); 5. mRS score = 2 for the first onset or before onset; 6. When screening, the National Institutes of Health Stroke Scale (NIHSS) scores from 3 to 25 (including both ends); 7. Female and male participants with fertility must agree to use efficient contraception measures from the signing of the informed consent form until one month after the last administration of the investigational drug, without a birth plan, and without donating sperm/eggs. (See "Contraceptive methods" in the attachment for details). Exclusion Criteria: 1. Treatment with ateplase, teneplase, or other thrombolytic drugs; 2. Proposed endovascular treatment; 3. Intracranial hemorrhagic diseases; 4. Aortic arch dissection; 5. NIHSS awareness score 1a>2 points; 6. Epileptic seizures or neurological dysfunction after seizures, or combined with other neurological/psychiatric disorders leading to uncooperative or non cooperative physical examinations; 7. Non enhanced CT shows a low-density shadow greater than one-third of the blood supply area of the middle cerebral artery or an ASPECT score of less than 6 points in the anterior circulation; 8. Previous history of intracranial hemorrhage; 9. Intracranial tumors, arteriovenous malformations, and aneurysms; 10. Extracranial carotid artery dissection and acute occlusion of the internal carotid artery; 11. Multiple infarcts in areas supplied by multiple large blood vessels; 12. Have a history of ischemic stroke, severe traumatic brain injury, or intracranial or spinal surgery in the past month; 13. Gastrointestinal or urinary system bleeding within the past 2 weeks; 14. Major surgical procedures or severe injuries within the past 2 weeks; 15. Arterial puncture that is difficult to compress and stop bleeding within the past week; 16. Active visceral bleeding; 17. After actively reducing blood pressure, systolic blood pressure = 180mmHg and/or diastolic blood pressure = 100mmHg; 18. Screening period examination: Blood glucose<2.8 or>22.2mmol/L, platelet<100 * 109/L APTT or PT is greater than the upper limit of normal value; 19. Within the past 3 months, acute ST segment elevation myocardial infarction (MI) and/or acute decompensated heart failure occurred, and/or QTc>520 milliseconds, and/or due to acute coronary syndrome MI? Hospitalization or involuntary coronary intervention for cardiac arrest; Or New York Heart Association Grade III/IV heart failure; Or known to have ventricular tachycardia; 20. History of severe liver disease, or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or glutamyltransferase (GGT) = 3 x ULN and/or total bilirubin (TBIL) = 2 x ULN. 21. Severe kidney disease with clinical significance, or eGFR<45mL/min/1.73 m2; 22. Subjects with known potential bleeding constitution or coagulation dysfunction; 23. Subjects with a known history of glucose-6-phosphate dehydrogenase deficiency or a family history; 24. Known to be allergic to any component of HRS-7450 or its formulations or placebo; 25. Received therapeutic or prophylactic doses of heparin treatment within 24 hours; 26. Oral coumarin anticoagulants with an international standardized ratio INR>2.7; 27. Use thrombin inhibitors, Xa factor inhibitors, or other anticoagulant drugs under study within48 hours; 28. Use platelet IIb/IIIa receptor inhibitors within 48 hours; 29. Pregnant women, or women of childbearing age who test positive for pregnancy, or those who are breastfeeding; 30. Participate in clinical studies of other drugs or devices within the first three months of the screening period (sign an informed consent form and receive treatment with the trial drug/device); 31. The terminal state of the disease, with an expected survival period of no more than 1 year; 32. Other situations where the researcher deems it inappropriate to participate in this experiment.

Study Design


Intervention

Drug:
HRS-7450
HRS-7450 Injection
0.9% sodium chloride injection
0.9% sodium chloride injection

Locations

Country Name City State
China The First Affiliated Hospital of Sun Yat sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Fujian Shengdi Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Symptomatic Intracranial Hemorrhage within 36 hours after the start of administration, The incidence of sICH within 36 hours after the start of administration
Secondary 7 day mortality rate after administration within 7days after the start of administration
Secondary The incidence of sICH 7 days after administration within 7days after the start of administration
Secondary The incidence of ICH 7 days after administration within 7days after the start of administration
Secondary The incidence of systemic bleeding 7 days after administration within 7days after the start of administration
Secondary Effective reperfusion rate measured by 24-hour PWI or CTP within 24 hours after the start of administration
Secondary 24-hour MRA or CTA measurement of vascular reperfusion rate within 24 hours after the start of administration
Secondary Infarct core volume measured by CT or MRI at 5-7 days within 5-7days after the start of administration
Secondary 24-hour NIHSS score change within 24 hours after the start of administration
Secondary 24-hour good response rate (NIHSS score reduction greater than 8 points, or NIHSS score 0-1) within 24 hours after the start of administration
Secondary 7 day NIHSS score change within 7days after the start of administration
Secondary 7 day good response rate (NIHSS score reduction greater than 8 points, or NIHSS score 0-1) within 7days after the start of administration
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3